UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) ~~December~~January 307, ~~2009~~ 2010

VION PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)


Delaware	000-26534	13-3671221

(State or Other Jurisdiction	(Commission	(IRS Employer
of Incorporation)	File Number)	Identification No.)


4 Science Park, New Haven, CT		06511

(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (203) 498-4210

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~o Soliciting~~Item 7.01. ~~material pursuant to Rule~~Regulation ~~14a-12~~FD ~~under the Exchange Act (17 CFR 240.14a-12)~~Disclosure

~~o Pre-commencement~~As ~~communications~~previously ~~pursuant~~disclosed, toon ~~Rule~~December ~~14d-2~~17, 2009, Vion Pharmaceuticals, Inc. (bthe “Registrant”) filed a voluntary petition for relief under chapter 11 of title 11 of the ~~Exchange~~United ~~Act~~States Bankruptcy Code (17the ~~CFR~~“Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the ~~240~~“Bankruptcy Court”) Case No.~~14d~~ 09-214429 (bCSS)).

~~o Pre-commencement~~On ~~communications~~January 7, ~~pursuant~~2009, tothe ~~Rule 13e-4~~Registrant filed its unaudited initial monthly operating report (cthe “Monthly Operating Report”) ~~under~~with the ~~Exchange~~Bankruptcy ~~Act~~Court. ~~(17~~A ~~CFR~~copy of the Monthly Operating Report is contained in the attached ~~240~~Exhibit 99.~~13e-4(c))~~1 and is incorporated herein by reference.

~~Item 8.01~~Limitation ~~Other~~on ~~Events.~~Incorporation by Reference

OnIn ~~December 30,~~accordance ~~2009,~~with ~~Vion~~General ~~Pharmaceuticals,~~Instruction ~~Inc~~B.2 ~~(the~~of ~~“Company”)~~Form ~~announced~~8-K, ~~that~~ the Uinformation in this Item 7.S.01 ~~Food~~is being furnished for informational purposes only and ~~Drug~~shall ~~Administration~~not (be deemed “~~FDA~~filed”) ~~had~~for ~~responded~~purposes toof ~~its~~Section 18 ~~Special~~of ~~Protocol~~the ~~Assessment~~Exchange ~~(“SPA”)~~Act, ~~request~~or otherwise subject to ~~evaluate~~ the ~~Phase III~~liabilities ~~randomized~~of ~~trial~~that ~~HOVON~~section, ~~AML~~nor 92shall ~~sponsored~~such information be deemed incorporated by ~~the~~reference ~~Dutch-Belgian~~in ~~Cooperative Group~~any ~~for~~filing ~~Hematology~~under ~~Oncology~~the ~~(“HOVON”)~~Securities Act of ~~its~~1933, ~~lead~~as amended, ~~product~~except ~~Onrigin™~~as otherwise expressly stated in such filing. The ~~FDA~~filing ~~raised~~of ~~concerns~~this ~~with~~Form 8-K shall not ~~the~~be ~~HOVON~~deemed ~~trial~~an ~~design~~admission ~~and~~as ~~requested~~to ~~modifications~~the ~~that~~materiality ~~would~~of ~~require~~any ainformation ~~new~~herein ~~Phase III~~that ~~trial~~is ~~at significant~~required ~~additional~~to ~~time~~be disclosed ~~and~~solely ~~expense~~by Regulation FD.

~~The~~Cautionary ~~Company~~Statement ~~will~~Regarding ~~evaluate~~Financial ~~whether~~and toOperating ~~file another SPA for an alternative randomized Phase III~~Data trial within the next two weeks. In this context, the SPA process is intended to evaluate a Phase III protocol whose data will form the primary basis for an efficacy claim. The Phase III randomized trial in acute myeloid leukemia (“AML”) is in response to the FDA’s complete response letter to the Company’s New Drug Application for Onrigin™ requiring that a randomized trial be conducted to support the approval of Onrigin™ for the treatment of AML.

AThe ~~copy~~Registrant ofcautions investors and potential investors not to place undue reliance upon the information ~~press~~contained ~~release~~in ~~announcing~~the Monthly Operating Report, which was not prepared for the ~~response~~purpose of providing the basis for an investment decision relating to any of the ~~SPA~~securities of the Registrant. The Monthly Operating Report has been prepared solely for the purpose of complying with the monthly reporting requirements of, and is ~~attached~~in asa ~~Exhibit 99~~format acceptable to, the Bankruptcy Court.1 The ~~hereto~~Monthly Operating Report is limited in scope and ~~incorporated~~only bycovers ~~reference~~a ~~herein~~limited time period.

~~Item 9~~The Monthly Operating Report was not audited or reviewed by independent accountants and was not prepared in accordance with accounting principles generally accepted in the United States of America (GAAP).01 ~~Financial~~There ~~Statements~~can be no assurance that, from the perspective of an investor or a potential investor in the Registrant’s securities, the Monthly Operating Report is complete. The Monthly Operating Report may be subject to future adjustment and ~~Exhibits~~reconciliation. The Monthly Operating Report also contains information for periods which are shorter or otherwise different from those required in the Registrant’s reports pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and such information might not be indicative of the Registrant’s financial condition or operating results for the period that would be reflected in the Registrant’s financial statements or in its reports pursuant to the Exchange Act. The information set forth in the Monthly Operating Report should not be viewed as indicative of future results.

The Monthly Operating Report and additional information about the Debtors’ filings under the Bankruptcy Code, including access to court documents and other general information about the Chapter 11 Case, are available online at the Registrant’s claims administration website located at http://www.delclaims.com/caseinfo/C09-14429.html.

Cautionary Statement Regarding Forward-Looking Statements

This Current Report on Form 8-K and its exhibit contain forward-looking statements that are subject to certain risks and uncertainties that could cause the Registrant’s plans or actual results to differ materially from those projected, including the Registrant being unsuccessful in selling its assets or engaging in another transaction in bankruptcy, the FDA failing to approve a Special Protocol Assessment for a Phase III randomized trial for Onrigin™ , the Registrant not obtaining court approval of its motions in the Chapter 11 proceeding pursued by it from time to time, the Registrant’s ability to develop, pursue, confirm and consummate one or more plans of reorganization with respect to the Chapter 11 case, the Registrant’s ability to retain and compensate key executives and other key employees, the Registrant’s ability to maintain relationships with its licensor and vendors, the Registrant’s potential inability to obtain regulatory approval for its products, particularly Onrigin™, delays in the regulatory approval process, particularly for Onrigin™, delays or unfavorable results of drug trials, the need for additional research and testing, including the need for a randomized trial of Onrigin™ prior to regulatory approval, the inability to manufacture product, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations

as a result, and a variety of other risks set forth from time to time in the Registrant’s filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, “Risk Factors” in the Registrant’s Form 10-K for the year ended December 31, 2008 and the Registrant’s Form 10-Q for the quarter ended September 30, 2009. The cautionary statements provided above are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the “ Act ”) and with the intention of obtaining the benefits of the “safe harbor” provisions of the Act for any such forward-looking statements. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, the Registrant does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

EXHIBIT NO.		DESCRIPTION
Exhibit
99.1		Press release dated December 30, 2009
Number		Description
99.1		Vion Pharmaceuticals, Inc. Initial Monthly Operating Report filed with the United States Bankruptcy Court for the District of Delaware.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VION PHARMACEUTICALS, INC.
Date: December 31, 2009	By:	/s/ Howard B. Johnson
Date: January 7, 2010	By:	/s/ Howard B. Johnson
		Name:	Howard B. Johnson
		Title:	President and Chief Financial Officer

EXHIBIT INDEX

EXHIBIT NO.		~~DESCRIPTION~~		DESCRIPTION
~~99.1~~	99.1	~~Press release dated December 30, 2009~~		Vion Pharmaceuticals, Inc. Initial Monthly Operating Report filed with the United States Bankruptcy Court for the District of Delaware

Filing Compare · VION PHARMACEUTICALS INC